XOMA’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a report released on Friday, Benzinga reports. The brokerage currently has a $117.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com raised XOMA from a sell rating to a hold rating in a research note on Wednesday, August 14th.

XOMA Trading Down 5.6 %

XOMA opened at $28.19 on Friday. XOMA has a twelve month low of $13.48 and a twelve month high of $30.36. The company has a 50-day simple moving average of $27.51 and a 200 day simple moving average of $25.89. The company has a quick ratio of 8.71, a current ratio of 8.71 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $328.10 million, a price-to-earnings ratio of -7.19 and a beta of 0.93.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $11.09 million for the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. Analysts predict that XOMA will post -1.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its stake in shares of XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA in the first quarter valued at approximately $212,000. Bank of New York Mellon Corp increased its stake in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,334 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.